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Abstract
Persistent latent reservoir of replication-competent proviruses in memory CD4 T cells is a major obstacle to curing HIV
infection. Pharmacological activation of HIV expression in latently infected cells is being explored as one of the strategies to
deplete the latent HIV reservoir. In this study, we characterized the ability of romidepsin (RMD), a histone deacetylase
inhibitor approved for the treatment of T-cell lymphomas, to activate the expression of latent HIV. In an in vitro T-cell model
of HIV latency, RMD was the most potent inducer of HIV (EC50 = 4.5 nM) compared with vorinostat (VOR; EC50 = 3,950 nM)
and other histone deacetylase (HDAC) inhibitors in clinical development including panobinostat (PNB; EC50 = 10 nM). The
HIV induction potencies of RMD, VOR, and PNB paralleled their inhibitory activities against multiple human HDAC
isoenzymes. In both resting and memory CD4 T cells isolated from HIV-infected patients on suppressive combination
antiretroviral therapy (cART), a 4-hour exposure to 40 nM RMD induced a mean 6-fold increase in intracellular HIV RNA
levels, whereas a 24-hour treatment with 1 mM VOR resulted in 2- to 3-fold increases. RMD-induced intracellular HIV RNA
expression persisted for 48 hours and correlated with sustained inhibition of cell-associated HDAC activity. By comparison,
the induction of HIV RNA by VOR and PNB was transient and diminished after 24 hours. RMD also increased levels of
extracellular HIV RNA and virions from both memory and resting CD4 T-cell cultures. The activation of HIV expression was
observed at RMD concentrations below the drug plasma levels achieved by doses used in patients treated for T-cell
lymphomas. In conclusion, RMD induces HIV expression ex vivo at concentrations that can be achieved clinically, indicating
that the drug may reactivate latent HIV in patients on suppressive cART.
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Introduction
Combination antiretroviral therapy (cART) has dramatically
improved the life expectancy and health of patients infected with
HIV. In the setting of controlled clinical trials with optimal cART,
up to 90% of treatment-naı¨ve patients can achieve undetectable
virus in plasma and normalization of CD4 T-cell levels [1,2].
However, when cART is interrupted in patients who initiated
therapy during the chronic phase of infection, virus replication
resumes in virtually all patients [3–5], indicating that current
cART is not sufficient to cure HIV infection. The failure of
cART to cure HIV infection is due, in part, to the ability of
HIV to establish latency in a subset of infected CD4 T cells [6].
The state of latency is characterized by the presence of inte-
grated but transcriptionally silent proviral HIV DNA, which
makes the infected cells invisible to the immune system and
resistant to both innate antiviral defenses and antiretroviral
therapy [6,7].
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Although latent proviral DNA has been detected in multiple
different immune cell subsets permissive to HIV infection, long-
lived resting memory CD4 T cells are believed to represent the
predominant reservoir of proviruses that can be activated to
produce infectious virions [8,9]. Initial quantification of latent
HIV proviruses in peripheral blood lymphocytes from patients on
cART revealed approximately 200 copies per 106 resting CD4 T
cells; however, in general, less than 1% of these proviruses was
shown to produce infectious HIV after T-cell mitogenic stimula-
tion with substantial inter-patient variation observed in the
fraction of total proviruses that could be activated [10]. The pool
of latently infected memory CD4 T cells is believed to be
maintained throughout a patient’s life by homeostatic proliferation
of memory T cells and/or intermittent antigen-driven clonal
expansion [11]. Alternatively, low levels of HIV replication
confined to lymphatic tissues and undetectable in the periphery
may also contribute to the maintenance of the latent virus
reservoir [11,12]. The decay rate of latent virus reservoirs in
peripheral blood lymphocytes has been estimated to have a half-
life of .3 years, indicating that even life-long cART is unlikely to
cure HIV infection [7].
Chronic HIV infection, even when suppressed by cART, poses
long-term health risks that include accelerated cardiovascular
disease, liver and renal disease, non-AIDS-associated cancers,
neurocognitive impairment, and accelerated senescence of im-
mune responses [13–15]. Thus, there is a clear unmet medical
need for novel therapeutic interventions that could lead either to
host-mediated control of HIV in the absence of cART or complete
clearance of viral reservoirs. Such virus eradication interventions
will need to be well tolerated with minimal side effects.
Specifically, therapeutic interventions need to be found that do
not cause global T cell activation or a chronic state of
inflammation. These interventions should also exhibit minimal
drug-drug interactions with medications frequently administered
to HIV-infected patients.
Identifying a safe modality to activate latent HIV in memory
CD4 T cells is an important goal and potentially represents the
first key step towards a cure for HIV. Establishment and
maintenance of HIV latency is a complex process that appears
to involve multiple mechanisms restricting productive viral
transcription. These mechanisms include promoter occlusion via
steric hindrance, insufficient levels of cellular transcription factors,
modification of the HIV 59 long-terminal repeat (LTR) by
methylation and alteration of the chromatin environment in the
vicinity of the LTR by histone deacetylation and other epigenetic
modifications [16,17]. Histone deacetylases (HDACs) have been
implicated in maintaining HIV in a latent state. In this process,
HDACs are recruited to the LTR by various transcriptional
regulators and deacetylate lysine residues on histones, inducing
chromatin condensation, thereby repressing proviral transcription
[18,19]. Consistent with this mechanism, HDAC inhibitors
(HDACi) have been reported to activate latent HIV in cell lines
and primary cells, including CD4 T cells from HIV-infected
patients on cART [20,21]. Vorinostat (suberoylanilide hydroxamic
acid; VOR) is an HDACi approved for clinical use to treat
cutaneous T-cell lymphomas and has also been shown to activate
HIV transcription in various latency models [22–24]. Adminis-
tration of a single dose of VOR to eight HIV-infected patients on
cART increased HIV RNA levels in resting CD4 T-cells by a
mean of 4.8-fold [25]. Although it is unclear whether a single dose
of VOR diminished the activatable latent HIV reservoir, these
results represent an important milestone by demonstrating that
HIV expression can be increased pharmacologically in HIV-
infected patients on cART.
In a recent study exploring a panel of HDACi for HIV
activation using an in vitro latency assay, panobinostat (LBH589;
PNB) displayed superior potency to multiple other HDACi tested
including givinostat, belinostat, and VOR [26]. Notably, a potent
HDACi romidepsin (RMD; Istodax) was not tested in this study.
RMD is a cyclic peptide naturally synthesized by Chromobacterium
violaceum [27] that has received regulatory approval for the
treatment of patients with peripheral T-cell lymphomas (PTCL)
or cutaneous T-cell lymphoma (CTCL) [28].
The present study explores the ability of RMD, in comparison
with VOR and other HDACi currently in clinical development, to
reverse HIV latency in vitro in primary T cells infected with a
reporter virus as well as ex vivo in resting and memory CD4 T
cells from HIV-infected patients on suppressive cART.
Results
Romidepsin is a potent activator of HIV in an in vitro
model of latency
To assess clinically tested HDACi for their ability to activate
HIV from latency, we first employed a previously described in
vitro HIV latency model [29,30] with several modifications to
increase the sensitivity of detection. The assay involves freshly
isolated naı¨ve CD4 T cells from healthy donors polarized to a Th0
phenotype, which mimics memory CD4 T cells. These Th0 cells
are then infected with HIV expressing a luciferase reporter gene
and cultured for an additional 7 to 10 days until a latent infection
is established.
The HDACi that we tested in this in vitro HIV latency assay
included RMD, VOR, PNB, givinostat, mocetinostat, and
pracinostat (SB939). All compounds showed dose-dependent
activity in the assay, but displayed varying levels of potency in
activating HIV expression (Fig. 1A). Based on experiments
conducted with cells prepared from three independent donors,
RMD was the most potent HDACi with a mean EC50 value of
4.5 nM (Table 1). Global T-cell activators such as anti-CD3/
CD28 antibodies and PMA+ ionomycin consistently showed 2- to
4-fold higher maximum induction of the luciferase signal relative
Author Summary
Combination antiretroviral therapy has greatly improved
the clinical outcome of HIV infection treatment. However,
latent viral reservoirs established primarily in memory CD4
T cells persist even after long periods of suppressive
antiretroviral therapy, which hinders the ability to achieve
a prolonged drug-free remission or a cure of the HIV
infection. Activation of HIV expression from latent reser-
voirs is a part of proposed strategies that may potentially
lead to virus elimination and ultimately cure of the
infection. In this study, we show that romidepsin, a
histone deacetylase inhibitor approved for the treatment
of T-cell lymphomas, is a potent activator of HIV expression
in an in vitro model of viral latency as well as ex vivo in
resting and memory CD4 T cells isolated from HIV-infected
patients with suppressed viremia. Importantly, the ex vivo
activation of latent HIV occurred at romidepsin concen-
trations lower than those achieved in drug-treated
lymphoma patients. In addition, romidepsin exhibited a
more potent effect than other drugs in the same class that
have already been shown to activate HIV expression in
vivo. Together, these results support the clinical assess-
ment of romidepsin in HIV-infected patients on suppres-
sive antiretroviral therapy.
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to RMD (data not shown). When cytotoxicity was determined
under the identical conditions, RMD displayed a CC50 (50% cell
viability reduction) value of 100 nM, resulting in an approximately
20-fold selectivity window (Table 1). PNB was the second most
potent compound tested with an EC50 value of 10 nM and a
relatively high selectivity window of .250-fold. VOR was
substantially less potent in this assay with EC50 and CC50 values
of 4 mM and .25 mM, respectively.
To confirm that the HDACi were activating HIV expression in
this latency model, we used flow cytometry analysis to quantify
intracellular p24 antigen levels following treatment of latently
infected CD4 T-cell cultures with RMD, VOR, and the positive
control anti-CD3/CD28 antibodies (Fig. 1B). Treatment with 5 and
80 nM RMD, representing the minimal and maximal concentra-
tions leading to the activation of HIV expression in this model,
resulted in 3.3% and 5.5% of cells expressing p24 antigen,
respectively. In comparison, treatment with 3.0 mM VOR induced
p24 antigen expression in approximately 4.4% of cells. As expected,
anti-CD3/CD28 antibodies induced p24 antigen expression in 2- to
3-fold higher fractions of CD4 T cells than RMD (Fig. 1B). While
the p24 expression in anti-CD3/CD28-treated cells reached a
plateau at 48 hours, the fraction of p24 positive cells in RMD-
treated cultures continued to increase for 72 hours (Fig. 1C). These
data indicate that RMD induces the expression of HIV proteins
following the activation of latent provirus in vitro.
HIV activation by HDACi correlates with the inhibition of
HDAC isoenzymes
Since the specific mechanism of HIV latency reversal by
HDACi remains to be fully understood, we investigated whether
the relative potency of selected compounds in the HIV latency
assay correlates with their ability to directly inhibit the activity of
individual HDAC isoenzymes. RMD, VOR, and PNB were tested
against 11 individual HDAC isoenzymes (HDAC-1 to -11) from
four distinct classes: 1, 2a, 2b, and 4. Overall, RMD was the most
potent inhibitor, especially against class 1 HDACs (HDAC-1 to -3)
as well as HDAC-10 and HDAC-11 isoenzymes (Table 2). PNB
Figure 1. In vitro activation of HIV expression by HDAC
inhibitors in an in vitro latency model. Primary CD4 T cells latently
infected in vitro with reporter HIV were established as previously
described [29,30] with additional minor modifications described in
Materials and Methods. The infected cells were incubated in the
presence of the indicated HDACi. (A) A dose response of HIV activation
by HDACi was determined by the quantification of luciferase reporter
activity after a 48-hour treatment. Results are mean 6 SD from a
representative experiment performed in quadruplicate. (B) Induction of
p24 expression by RMD and VOR. Flow cytometry analysis of cells from
a representative donor is shown with gating on the live cell population.
Anti-CD3/CD28 antibodies conjugated to beads were used as a positive
control. (C) Time course of the induction of p24 expression by RMD.
Cells isolated from 2 independent donors were treated with 40 nM
RMD or anti-CD3/CD28 antibodies for 24 to 72 hours in the presence of
antiretrovirals. Percentage of p24-positive cells was determined by flow
cytometry with gating on live cell population.
doi:10.1371/journal.ppat.1004071.g001
Table 1. Activity and cytotoxicity of HDAC inhibitors in the in
vitro HIV latency model.
EC50 (nM) CC50 (nM)
RMD 4.561.0 1076126
VOR 3,95061,900 .25,000
PNB 10.161.0 .2,500
Givinostat 95.8620.3 24,00065,020
Mocetinostat 13,60064,664 10,1006106
SB939 212614 .50,000
Latently infected primary CD4 T cells prepared from three independent healthy
donors were treated with the indicated compounds continuously for 48 hours.
EC50 and CC50 values were determined from each dose-dependent response
using a multi-parameter algorithm. Data are mean 6 SD from three
independent experiments performed in quadruplicate.
doi:10.1371/journal.ppat.1004071.t001
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showed lower potency, particularly against class 1 and 4 enzymes
with up to 40-fold higher IC50 values relative to RMD. VOR was
a substantially weaker inhibitor of the majority of HDAC enzymes
than RMD with the exception of HDAC-6. The greatest
difference in potency between RMD and VOR was observed
with the class 1 HDAC enzymes that were 60- to 2,500-fold more
susceptible to RMD than VOR (Table 2). The greater activity of
RMD against a broad range of HDAC enzymes correlated with its
higher potency to activate HIV expression relative to VOR
(,1,000-fold difference; compare Tables 1 and 2).
RMD activates latent HIV ex vivo in CD4 T cells from
virally suppressed patients
Previous studies revealed that VOR activates HIV transcription
ex vivo in resting CD4 T cells isolated from HIV-infected patients
on cART [21]. We used a similar approach to compare RMD to
VOR in total memory as well as resting CD4 T cells isolated from
patients chronically infected with HIV who were treated with
cART and maintained their plasma HIV RNA at ,50 copies/ml
for at least 12 months (See Supplementary Table S1 for patient
descriptions). In the initial set of experiments, isolated CD4 cells
were treated with 40 nM RMD for 4 hours or 1 mM VOR for up
to 24 hours to mimic the clinical exposure profiles of these drugs.
To examine the kinetics of HIV induction, we analyzed cell-
associated viral RNA levels at 6, 12, 24, and 48 hours after
treatment initiation. Consistent with the data of Archin et al. [21],
a 2- to 4-fold increase in HIV RNA levels was observed both in
memory and resting CD4 T cells after 6 hours of VOR treatment
compared with control vehicle (DMSO)-treated cells (Fig. 2).
However, HIV RNA in VOR-treated cells decreased by 48 hours
to levels detected in vehicle-treated cells. In contrast, cell-
associated HIV RNA continued to increase in both memory and
resting CD4 T cells isolated from the same donors following their
exposure to RMD (Fig. 2). Levels of intracellular HIV RNA in
both cell types were 5- to 6-fold higher compared with vehicle-
treated controls and peaked between 24 and 48 hours after the
addition of RMD. These findings suggest that the activation of
HIV transcription with RMD is more durable than with VOR.
Ex vivo treatment with RMD induces a release of
extracellular HIV RNA
We next examined whether RMD and VOR induce the release
of HIV particles from patient-derived memory and resting CD4 T
cells. We used HIV RNA in cell culture supernatants as a
surrogate marker for virion release from treated cells. We assumed
that extracellular virions would accumulate over the course of
several days; therefore, the duration of culture was extended to 6
days to maximize assay sensitivity. Memory CD4 T cells from
multiple patients were treated with 5 and 20 nM RMD for
4 hours, or 0.5 and 1 mM VOR for 24 hours. Under these
conditions, RMD, but not VOR, increased extracellular HIV
RNA in culture supernatants of memory CD4 cells isolated from
multiple HIV-infected virally suppressed patients (Fig. 3A). The
release of viral RNA from cells treated with RMD is unlikely to be
due to cytotoxicity of the compound because the tested
concentrations did not substantially affect cell viability (Supple-
mentary Fig. S1). In addition, highly cytotoxic compounds such as
blasticidine caused .80% cell death during the same incubation
period, but did not lead to release of detectable levels of HIV RNA
into cell culture supernatants (data not shown).
To determine whether the observed lack of HIVRNA release from
cells treated with VOR was due to an insufficient duration of drug
treatment, memory and resting CD4 T cells isolated from HIV-
infected patients on cART were treated with 1 mM VOR for 6 days.
Similar to the cultures treated with VOR for 24 hours, there was no
significant increase in HIV RNA in culture supernatants following a
6-day VOR treatment of memory CD4 T cells isolated from two
HIV-infected patients on suppressive cART. In contrast, continuous
6-day treatment with RMD resulted in the detection of extracellular
HIVRNA inmemory CD4T-cell cultures from themajority of tested
donors (Fig. 3B). Continuous treatment with RMD was conducted at
a lower drug concentration (5 nM) to avoid cytotoxicity. Similarly,
2.5 nM RMD induced HIV RNA release in resting CD4 T-cell
cultures from 6 of 8 tested donors. In comparison, treatment of resting
CD4 T cells with 1 mM VOR resulted in a measurable increase of
extracellular HIV RNA in 3 of 7 patient-derived cultures tested, but
0.5 mM VOR did not increase extracellular HIV RNA significantly
above the levels of untreated controls (Fig. 3C). Importantly, HIV
RNA released into cell culture supernatants of the resting CD4 T cells
treated with RMD can be pelleted by high-speed centrifugation,
supporting the conclusion that the extracellular HIV RNA is
associated with virion particles (Supplementary Table S2).
HIV activation correlates with the inhibition of HDAC
activity in resting CD4 T cells
Although the relative in vitro HIV activation potency of RMD,
VOR, and PNB correlated with the inhibitory activity of these
compounds against multiple HDAC isoforms, we next set out to
determine whether inhibition of cellular HDAC activity in latently
infected cells also correlated with HIV activation. To address this
question, resting CD4 T cells isolated from three cART-suppressed
HIV-infected patients were treated with RMD, VOR, or PNB, and
activation of intracellular HIV RNA expression was determined in
parallel with cell-associated HDAC enzymatic activity. We found
that the activation of HIV expression correlated with HDAC
inhibition across multiple time points ranging from 6 to 48 hours
(Fig. 4). In RMD-treated cells, both HIV activation and cell-
associated HDAC inhibition persisted throughout the 48-hour
incubation period. In contrast, the inhibition of HDAC activity by
Table 2. Effect of RMD, VOR, and PNB on the activity of
individual human HDAC isoenzymes.
IC50 (nM)
HDAC Class Enzyme RMD VOR PNB
1 HDAC-1 0.102 148 4.35
HDAC-2 0.376 418 5.28
HDAC-3 0.211 509 6.04
HDAC-8 24.6 1,700 31.9
2a HDAC-4 314 27,000 442
HDAC-5 1,160 20,800 336
HDAC-7 3,405 101,550 10,825
HDAC-9 8,910 31,650 4,805
2b HDAC-6 488 27.1 5.74
HDAC-10 0.133 527 2.54
4 HDAC-11 0.407 504 9.56
Recombinant human HDAC isoenzymes were incubated with the indicated
HDACi and fluorogenic peptide substrates as described in Materials and
Methods. IC50 values were calculated from 10-point dose-response curves using
a multi-parameter curve fit. Data represent mean values from two independent
experiments.
doi:10.1371/journal.ppat.1004071.t002
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VOR and PNB was transient and decreased after 24 hours of
incubation, which paralleled the levels of cell-associated HIV RNA
over time (Fig. 4). Concentrations of VOR and PNB used in these
experiments corresponded to 100% systemic drug exposure
observed in treated cancer patients, while the concentration of
RMD was 40% of the clinical drug exposure. These results reveal
that sustained inhibition of cell-associated HDAC activity by RMD
correlates with persistent activation of HIV expression.
RMD reactivates latent HIV in resting CD4 T cells at
concentrations substantially below those achieved
during clinical dosing
Since RMD-related toxicities have been observed at doses used
for the clinical treatment of hematologic malignancies [31,32], we
tested whether RMD can activate latent HIV in patient-derived
CD4 T cells at concentrations below its clinical exposure achieved
with the dose of 14 mg/m2 used for the treatment of lymphomas
[33]. Resting CD4 T cells from three HIV-infected patients were
treated ex vivo with 3.5 to 40 nM RMD for 4 hours to mimic 40%
or less of the systemic drug levels achieved during the i.v.
administration of the clinical dose based on the relative free drug
fraction in human plasma and cell culture media (Supplementary
Table S3). While minimal induction of HIV transcription in
resting CD4 T cells was observed with 3.5 nM RMD, treatment
with 15 or 40 nM RMD induced 4- to 6-fold activation of HIV
RNA expression (Fig. 5). This contrasted with results obtained
following treatment with 1 mM VOR, which induced rapid, but
transient and less-pronounced activation of latent HIV expression
(Fig. 2 and Fig. 4A). Based on the measured free drug
Figure 2. Ex vivo activation of HIV expression by RMD and VOR. CD4 T cells were isolated from virally suppressed HIV-infected patients and
pulse-treated with RMD and VOR for 6 and 24 hours, respectively. Cell-associated total RNA was extracted, HIV RNA levels were quantified at the
indicated time points, and fold increase in the cell-associated HIV RNA was determined relative to corresponding vehicle-treated control for each
individual time point. The fold change for each donor and condition is based on mean number of HIV copies from 4 to 5 independent measurements.
Red dashed line represents the mean fold HIV induction across all tested donors. Symbols # (p,0.01) and * (p,0.05) denote a statistically significant
difference between fold HIV induction by RMD and VOR across all donors tested. Data for each individual donor and condition including results of
statistical analysis are provided in Supplementary Table S4. (A) Memory CD4 T cells were purified as the CD4(+)CD45RA(2) subset. (B) Resting CD4+ T
cells were purified as the CD4(+)HLA-DR(2)CD69(2)CD25(2) subset.
doi:10.1371/journal.ppat.1004071.g002
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concentration in cell culture media and human serum, 1 mM
VOR is above the clinical exposure achieved in patients following
the oral administration of the clinical dose of 400 mg (Supple-
mentary Table S3). Thus, RMD is capable of durable induction of
HIV transcription in cells from HIV-infected patients on
suppressive cART at concentrations substantially below those
achieved in cancer patients following the administration of the
clinically approved dose of the drug.
RMD does not induce global activation of immune cells
HIV latency reversing agents that would be suitable for the
therapeutic use in vivo should not induce non-specific immune
activation. To determine if RMD may activate immune cells,
PBMCs isolated from HIV-infected subjects on suppressive cART
were treated with a 4-hour pulse of 15 or 40 nM RMD. The
activation status of selected immune cell subsets, including CD4+
and CD8+ T cells, as well as CD19+ B cells was assessed by flow
cytometry analysis of cellular activation markers relative to
treatment with either 1 mM VOR or vehicle control. While RMD
treatment induced dose-dependent expression of CD69 in 10% to
50% of T and B cells, it did not lead to any changes in the expression
of other prominent cell activation markers such as CD25 or HLA-
DR in any of the cell subsets (Fig. 6). In contrast to effects observed
in the context of complete PBMC cultures, RMD treatment
induced minimal increases in the fraction of CD69-positive cells in
resting CD4 T cells isolated from cART-suppressed HIV-infected
patients (Supplementary Fig. S2). In addition, no significant
induction of IFN-a, IFN-c, TNF- a, TGF-b, IL-2, IL-7 or other
cytokines were detected in PBMC cultures from the same patients
following the treatment with RMD (data not shown). Together,
these data indicate that RMD effectively activates the expression of
latent HIV without inducing the global activation of T or B cells.
RMD exhibits consistent ex vivo HIV activation in
longitudinal samples from the same donor
Recent results showed inter-patient variation in ex vivo HIV
activation by VOR [25]. Thus, it was important to determine
whether HIV reactivation by RMD was consistent in samples
collected longitudinally from the same patient over time. We
measured HIV RNA levels following RMD treatment of resting
CD4 T cells from three sequential blood samples collected several
weeks apart from the same two HIV-infected patients with
suppressed plasma viral load. One of the tested subjects showed
robust and reproducible dose-dependent HIV RNA increase in
culture supernatants after 7 days of RMD treatment in all three
longitudinal samples (Fig. 7; high-responding patient). Although
the other subject exhibited weaker HIV activation following
treatment with RMD, a concentration-dependent effect on viral
expression was observed in 2 of 3 longitudinal samples (Fig. 7; low-
responding patient). These results show that RMD is capable of
eliciting reproducible reactivation of latent HIV ex vivo in samples
collected longitudinally from the same patient.
Sequencing analysis of HIV induced by RMD
We used a single-genome sequencing (SGS) [34–36] approach
to analyze sequences of HIV gag-pol RNA in cell culture
supernatants of resting CD4 T cells from the high-responding
patient (depicted in Fig. 7) following the latency reversal by RMD
and compared those with sequences of HIV RNA induced by the
stimulation of CD3/CD28. In parallel, we assessed the sequence
diversity of HIV proviruses integrated in genomic DNA of resting
CD4 T cells from the same culture. The SGS analysis confirmed
the presence of multiple HIV RNA sequences in the supernatants
of resting CD4 T-cell cultures following a 7-day treatment with
RMD or anti-CD3/CD28 antibodies. Importantly, several provi-
ral DNA sequences were identified that matched some of the
RMD-induced HIV RNA sequences in culture supernatants
(Fig. 8). However, many proviruses did not have matching RNA
sequences induced in the cell culture supernatants. This is
consistent with previous observations that a large proportion of
integrated proviruses are refractory to the activation by latency
reversal agents [37]. Notably, a few instances were found in which
identical HIV RNA sequences were induced by both RMD and
anti-CD3/CD28 antibodies, but many HIV RNA sequences were
Figure 3. Induction of extracellular viral RNA release from CD4 T cells treated with RMD and VOR.Memory or resting CD4 T cells isolated
from HIV-infected patients on suppressive cART were treated with RMD or VOR, and viral RNA was quantified in cell culture supernatants 6 days after
the addition of drugs. Results are depicted as fold increase in viral RNA relative to control cultures. Each symbol represents one HIV subject. Solid
circles, p,0.05; open circles, p.0.05 compared to vehicle-treated controls from the same donors; solid squares, p value not calculated. Red lines
represent the mean fold HIV induction across all analyzed donors. Symbols # and * denote a statistically significant difference (p,0.05) for RMD-
mediated HIV induction vs. 0.5 and 1 mM VOR, respectively, across all tested donors. Data for each individual donor and condition including results of
the statistical analysis are summarized in Supplementary Table S4. (A) Memory CD4 T cells were treated with RMD and VOR for 4 and 24 hours,
respectively. (B) Memory CD4 T cells were treated continuously for 6 days. (C) Resting CD4 T cells were treated continuously for 6 days.
doi:10.1371/journal.ppat.1004071.g003
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also detected that are unique for each treatment. This is likely, at
least in part, due to different mechanisms by which the two stimuli
activate latent HIV. Although more extensive sequence analyses of
samples from a larger set of HIV-infected patients on suppressive
cART are needed to characterize proviruses that can be
specifically activated by RMD, these initial results further confirm
that RMD treatment activates a subset of latent HIV proviruses in
resting CD4 T cells.
Discussion
In this report, we show that the HDACi RMD acts as a potent
activator of latent HIV with effects observed in resting and
memory CD4 T cells either infected in vitro or isolated from HIV-
infected patients on cART with suppressed viremia. RMD was a
more potent inducer of HIV expression compared to VOR and
PNB, two HDACi that are being evaluated clinically in HIV-
infected patients on cART. The greater potency of RMD
compared with VOR to induce HIV expression was observed in
multiple patient samples and at multiple time points in both total
memory and resting CD4 T cells. RMD also exhibited a greater
magnitude and longer persistence of HIV RNA expression relative
to VOR, and was capable of inducing the release of HIV virions
from infected cells. The lasting effect of RMD compared to other
HDACi may be related to its unique intracellular pharmacology
and interaction with HDAC enzymes. RMD acts as an
intracellular prodrug that undergoes reduction of its intramolec-
ular disulfide bond upon entering cells [38]. The released free
sulfhydryl groups tightly interact with the Zn2+ ion in the active
site of various target HDAC isoforms, a mechanism of inhibition
that does not apply to VOR or PNB.
In addition, RMD activated latent HIV ex vivo in cells from
HIV-infected patients on cART at concentrations that are lower
than those achieved in cancer patients receiving the clinically
approved dose of 14 mg/m2. In patients with either hematologic
malignancies or solid tumors, RMD showed an acceptable short-
term safety profile and was not associated with severe toxicities
[33]. The most common adverse reactions related to once-weekly
dosing of RMD were thrombocytopenia, neutropenia, lymphope-
nia, nausea, and fatigue [33].
In our study, we observed reproducible ex vivo activation of
HIV by RMD at concentrations corresponding to systemic clinical
exposures expected after dosing at 2–5 mg/m2. Given these results
and the established clinical safety profile of RMD, clinical testing is
warranted to assess whether RMD can activate latent HIV and
potentially reduce the size of the latent reservoir in HIV-infected
patients on suppressive cART.
Recently, results from two clinical studies of single and multiple
doses of VOR administered to HIV-infected patients on cART
have been reported. The first study demonstrated a mean 4.8-fold
increase in cell-associated HIV RNA levels in resting CD4 T cells
following the administration of a single 400 mg dose of VOR to 8
subjects [25]. Another study examined once-daily dosing of VOR
for 14 consecutive days and reported an approximate 3-fold mean
increase in cell-associated HIV RNA levels in a cohort of 20
patients [39]. However, increases in the level of plasma viremia
were not observed in either study. This finding could be consistent
with our observation that VOR does not cause release of virions as
measured by extracellular HIV RNA. In addition to VOR,
multiple doses of PNB have been shown to induce intracellular
HIV transcription and low-level viremia in peripheral blood of
HIV-positive patients on suppressive cART [40].
Although monitoring the induction of HIV RNA expression in
resting CD4 T cells from virally suppressed subjects treated with
VOR was shown to be feasible, determining whether such
treatments with HDACi can affect the size of the latent virus
reservoir remains a challenge. There was no apparent effect on
total proviral DNA in peripheral CD4 T cells in the multiple-dose
(14-day) trial of VOR [39]. This outcome may be explained in
part due to the presence of a high background of defective
proviruses that cannot be activated and thus would not undergo
depletion from viral cytopathic effect or immune-based clearance.
In addition, Ho et al. recently showed that a large fraction of intact
proviruses are refractory to latency reversal [37]. Therefore, in
future clinical trials of HIV latency-reversing agents, it will be
critical to use methods that will allow more direct assessment of the
changes in the size of the inducible HIV reservoir following its
pharmacological activation.
Induction of HIV expression from latent reservoirs is being
pursued as a component of the reservoir eradication strategy that
may ultimately lead to a prolonged drug-free remission or even
cure [11,12]. It should be noted that RMD activates latent HIV to
Figure 4. Induction of HIV expression and inhibition of cell-
associated HDAC activity by HDACi. Resting CD4 T cells isolated
from cART-suppressed HIV-infected patients were pulse-treated with
RMD (4 hours), VOR (24 hours), and PNB (24 hours). Viral RNA was
determined 48 hours after the initiation of the treatment. Data
represent mean 6 SD from two independent donors. (A) Cell-
associated total RNA was extracted at the indicated time points, and
HIV RNA levels were quantified. Data for each individual donor and
condition including results of the statistical analysis are summarized in
Supplementary Table S4. (B) Total class I and II HDAC enzyme activity
was measured in total cell extracts of treated cells relative to vehicle-
treated cells (representing 100% activity) using a model substrate
described in Materials and Methods.
doi:10.1371/journal.ppat.1004071.g004
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a lesser degree than the mitogenic T-cell activators PMA+iono-
mycin or anti-CD3/CD28 antibodies; therefore, additional
significant efforts would likely have to be devoted to improving
the HIV activation effects of RMD. As already suggested, this may
potentially be achieved by combining HDACi with other latency-
reversing agents that work through complementary mechanisms.
For example, synergistic effects on HIV expression have been
documented in vitro between VOR and the PKC activator
prostratin [41]. Other classes of agents shown to activate latent
HIV in vitro and/or ex vivo include histone methyltransferase
inhibitors [42,43], as well as other small molecules such as
disulfiram [44,45]. Currently, however, no specific combination of
agents suitable for testing in patients has emerged. Therefore, in
future studies, the latency reversing agents should be considered
for testing in combination with RMD to identify potential
synergies for HIV activation. Concomitantly, any identified
combinations of synergistic agents would have to undergo rigorous
safety evaluations as the combined safety profiles of compounds
independently modulating gene expression cannot be easily
deduced.
At this early discovery stage of novel agents that activate latent
HIV, it is also important to realize that the fate of cells expressing
pharmacologically reactivated proviruses is not fully understood.
While acute HIV infection of CD4 T cells is associated with cell
death via both direct and bystander mechanisms, it is unknown
whether reactivation of latent HIV with RMD or other latency-
reversing agents would lead to virus-induced cell death. Recent
data generated in an in vitro model of HIV latency has shown that
HIV activation with VOR does not lead to cell death [46].
However, this result could be at least in part attributed to the
nature of the latency model that relied on the ectopic expression of
the anti-apoptotic factor Bcl2 to prolong the viability of the
latently infected cells and/or to other unrecognized differences
between in vitro models and the in vivo state. Addressing the fate
of infected CD4 T cells after virus reactivation with RMD is a high
priority of ongoing studies.
If reactivation of latent virus does not lead to cell death,
additional interventions would be needed to eliminate cells
expressing viral proteins. Strategies may include agents that
selectively enhance apoptosis in infected cells following the latency
reversal [47]. Other approaches under consideration include
antibody-based therapies to recruit immune effector cells such as
natural killer cells via antibody-dependent cell-mediated cytotox-
icity [48], a strategy that has been used clinically for the treatment
of various malignancies [49]. One potential advantage of the
antibody-mediated clearance of virally infected cells is the high
degree of selectivity of monoclonal antibodies for cells expressing
the HIV envelope antigen. However, it is unclear whether the
pharmacological activation of latent HIV will induce sufficient
levels of gp120/gp41 expression on the surface of the treated cells
to trigger an antibody-mediated effector mechanism resulting in
cell lysis. Although we and others have detected intracellular HIV
p24 capsid protein following treatment with HDACi using in vitro
HIV latency models, little is known about levels of viral protein
expression that can be induced by HDACi in latently infected
resting CD4 T cells from cART-treated patients. One of the major
challenges in addressing this question is the very low frequency of
T cells harboring latent HIV provirus in virally suppressed patients
[37]. New approaches to selectively enrich the fraction of latently
infected cells isolated from patients are being explored [50] and
may ultimately enable more in-depth characterization of RMD
and other latency-reversing agents.
It should be noted that the treatment with HDACi could modify
immune functions and responses (reviewed in [51,52]). Various
HDACi have been shown to inhibit innate immunity responses
and cytokine production [53,54] as well as immune cell trafficking
and functions [55–57]. While the clinical doses of RMD approved
for oncology applications can diminish responses of immune
effector cells in lymphoma patients [58], our data support the
exploration of lower doses of RMD for the activation of latent viral
reservoirs in HIV-infected patients. Such modified dosing
regimens could reduce or eliminate the perturbations of immune
functions potentially associated with RMD treatment. In addition,
treatment with agents that stimulate innate immunity such as
TLR7/8 agonists could mitigate the suppressive effects of RMD
on the activity of immune effector cells [58]. If RMD use
Figure 5. RMD activates intracellular HIV expression at concentrations below the levels achieved by clinical dosing. Resting CD4 T
cells were isolated from 3 cART-suppressed HIV-infected patients and pulse-treated with RMD for 4 hours with the indicated concentrations. Cell-
associated HIV RNA levels were analyzed at each time point following the treatment initiation (t = 0 hour), and fold induction was determined relative
to a background signal in vehicle-treated controls. Predicted i.v. dose and percentage of clinical exposure were calculated for each RMD
concentration tested relative to the clinically approved dose of 14 mg/m2; calculations were performed based on the free fraction of drug in human
plasma and cell culture media. Data represent mean6 SD from at least 3 HIV-infected donors. Data for each individual donor and condition including
results of the statistical analysis are summarized in Supplementary Table S4.
doi:10.1371/journal.ppat.1004071.g005
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eventually requires combination with immunostimulatory strate-
gies to enhance antiviral immune effector functions and the
clearance of latent HIV reservoirs, optimized temporal separation
in the administration of RMD and immune stimulators could
further minimize the potential of RMD-mediated interference
with immune responses.
In summary, this report shows that RMD is a more potent and
robust inducer of HIV expression in latently infected cells
compared with other HDACi in clinical testing. This profile
warrants the assessment of RMD in virally suppressed HIV-
infected patients.
Materials and Methods
Ethics statement
HIV-infected patients were enrolled into the study at the Quest
Clinical Research (QCR; San Francisco, CA) and the University
of Pittsburgh Medical Center (UPMC; Pittsburgh, PA). The QCR
and the UPMC part of the study were approved by the Western
Institutional Review Board and the University of Pittsburgh
Institutional Review Board, respectively. In both cases, written,
informed consent was obtained from the patients prior to any
study procedures.
HDAC inhibitors
Romidepsin was obtained from a US-based pharmacy as a
marketed commercial formulation of the drug. Vorinostat,
panobinostat, givinostat, mocetinostat and SB939 were obtained
from Selleck Chemicals (Houston, TX). Phorbol 12-myristate 13-
acetate (PMA) and ionomycin were obtained from Sigma Aldrich
(St. Louis, MO). All compounds were dissolved in DMSO. Effects
of HDAC inhibitors in all assays and models used in this study
have been compared to vehicle (i.e. DMSO) treated controls.
Construction of HIV expressing a luciferase reporter gene
Plasmid pKS13 is a NL4-3-based vector in which the vpr and env
genes were inactivated by inserting a ‘T’ base at the AflII site and
two bases (TT) at the NdeI site, respectively, causing frame shifts
in both open reading frames. A codon-optimized firefly luciferase
gene was introduced in place of the nef gene by replacing the
BamHI and NcoI fragment, yielding the plasmid pKS13. NL4-3-
Luc virus was generated by co-transfection of HEK-293T cells
with pKS13 and a plasmid containing the HIV-1 env gene using
Lipofectamine 2000 (Life Technologies, Grand Island, NY).
In vitro model of HIV latency
Total peripheral blood mononuclear cells (PBMCs) were
obtained from healthy HIV-negative donors by leukapheresis
(AllCells, Inc, Emeryville, CA). Naive CD4+ T cells were purified
by negative selection using EasySep magnetic beads (StemCells,
Inc, Vancouver, Canada) and cultured in RPMI with 10% fetal
bovine serum (FBS), penicillin/streptomycin, 1% nonessential
amino acids (Life Technologies, Carlsbad, CA), 1% sodium
pyruvate (Life Technologies) and 495 nM beta-mercaptoethanol
(Sigma Aldrich, St. Louis, MO) in a 37uC, 5% CO2 incubator.
Purified naive CD4+ T cells were activated by incubation with
anti-CD3/CD28 magnetic Dynabeads (1 bead: 2 cells ratio, Life
Technologies), 1 mg/ml anti-IL-4 (R&D Systems, Minneapolis,
MN), 2 mg/ml anti-IL-12p70 antibodies (R&D Systems), and
10 ng/ml TGF-b (R&D Systems) for 3 days [29,59]. Following the
removal of anti-CD3/CD28 beads and antibodies, cells were
maintained in 30 U/ml IL-2 (Life Technologies) for 2 days. Cells
were then infected with NL4.3-Luc in the presence of 50 mg/ml
DEAE for 3 hours. Cells were maintained in the continued
presence of 30 U/ml IL-2 throughout the infection and subse-
quent rest period with culture medium with fresh IL-2 replaced
every 2–3 days. Seven days post-infection, 20 ml of latently
infected cells were dispensed into 384 well plates using a MicroFlo
dispenser (Biotek Insturments, VT) at 10,000 cells/well containing
100 nl of compound solutions delivered by the Echo acoustic-
based liquid dispenser (Labcyte, Sunnyvale, CA). After a 48-hour
incubation, 16 ml/well BriteGlo (Promega, Madison, WI) was
added and luminescence measured using the Envision plate reader
(Perkin Elmer, Waltham, MA). Compound-associated cytotoxicity
was determined in latently infected cells in parallel with the virus
activation assay. Cells were incubated with compounds for
Figure 6. RMD does not induce global activation of immune
cell subsets. PBMCs isolated from four HIV-infected patients on
suppressive cART were treated with a 4-hour pulse of RMD or
continuously with vehicle control (DMSO), VOR, or PMA+ionomycin
and stained for surface markers 48 hours after the treatment initiation.
Fractions of CD692, CD252, and HLA-DR-positive cells in subsets of
CD4+ T cells, CD8+ T cells, and CD19+ B cells were analyzed by flow
cytometry as described in Materials and Methods. Each symbol
represents one donor.
doi:10.1371/journal.ppat.1004071.g006
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48 hours at 37uC, and cell viability was determined using Cell
Titer Glo reagent (Promega).
Flow cytometry analysis of p24 expression
Seven days post-infection, cells infected with NL4-3-Luc virus
were stimulated for 48 hours with test compounds. Cells were
stained with fixable viability dye v450 (eBioscience, San Diego,
CA) in phosphate buffered saline (PBS) +2% FBS for 30 minutes
at 4uC. Cells were fixed with IC Fixation Buffer (eBioscience) for
20 minutes at room temperature in the dark followed by treatment
with a permeabilization buffer (eBioscience) for 30 minutes at 4uC.
Intracellular p24 was stained with anti-p24 antibody clone KC57-
RD1 (Beckman Coulter, Fullerton, CA), then washed and
resuspended in PBS +2% FBS. The cells were analyzed on a
LSR Fortessa (BD Biosciences, San Jose, CA) and collected data
were processed using a FlowJo Analysis Software (TreeStar,
Ashland, OR).
HDAC inhibition assays
Determination of HDACi potency against individual HDAC
enzymes was performed at Reaction Biology Corporation (Malvern,
PA). In brief, human HDAC-1 to -11 enzymes were incubated with
serial dilutions of HDACi and fluorogenic peptide substrates
(50 mM) in a 96-well format assay. Concentrations of HDACi
reducing the control activity of tested enzymes by 50% (IC50) were
determined by a five-parameter curve fit of collected fluorescent
signals. Fluorogenic peptide derived from p53 protein (amino acid
residues 379–382; RHKKAc) was used as a substrate for HDAC
enzymes 1, 2, 3, 6, 10, and 11. A different fluorogenic peptide from
p53 (amino acid residues 379–382, RHKACKAC) was used as a
substrate for HDAC-8. Fluorogenic peptide Boc-Lys(trifluoroace-
tyl)-AMC was used as a substrate for HDAC enzymes 4, 5, 7, and 9.
Ex vivo activation of HIV transcription
HIV-infected patients participating in the study were selected
based on sustained plasma viral load suppression (,50 copies/ml
for .12 months), CD4 counts (.350 cells/mL), and absence of co-
infection with hepatitis B or C virus (Supplementary Table S1).
Clinical laboratory results were reconfirmed 2 weeks before
leukapheresis or blood draw. Leukapheresis was conducted for 3–
4 hours, and samples were processed within 2 hours after
collection. The leukapheresis product was diluted 1:1 with PBS
and layered over Ficoll for isolation of PBMCs. PBMCs were
treated with red blood cell lysis buffer (eBioscience) and rested
Figure 7. Ex vivo response to RMD in multiple longitudinal samples from the same donors. Resting CD4 T cells isolated from 2 cART-
suppressed HIV-infected patients were treated continuously with RMD or with anti-CD3/CD28 antibodies (AC, activation control) for 7 days. HIV RNA
in cell culture supernatants was quantified by COBAS on day 7. Data for a high-responding (A) and a low-responding donor (B) to RMD is shown;
each donor was tested at 3 different time points separated by at least 2 weeks (Exp 1–3). VC/NDC, vehicle control/no-drug control. Asterisk (*)
indicates no value due to COBAS analysis failure. Dashed lines indicate the limit of HIV quantification by COBAS (20 copies/ml). Data for each
individual donor and condition including results of the statistical analysis are summarized in Supplementary Table S4.
doi:10.1371/journal.ppat.1004071.g007
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overnight (10 million cells/ml) in tissue culture medium (RPMI
1640 supplemented with 10% FBS and PenStrep) before the
isolation of memory CD4 T cells according to the manufacturer’s
recommendation (EasySep Human Memory CD4 T cell Enrich-
ment Kit). Resting CD4 T cells were isolated by first enriching
total CD4 T cells (StemCell Technologies) and subsequently
depleting HLA-DR-, CD25-, and CD69-positive cells via negative
selection (Miltenyi Biotec, Auburn, CA). Flow cytometry was used
to assess the purity of both T-cell subsets (.98%). Resting CD4 T
cells for the analysis of continuous RMD exposure and longitu-
dinal responses to RMD in the same donors were purified from
fresh blood using the same protocol.
To assess HIV activation by HDACi, up to 5 million CD4 T
cells were plated in 24-well plates in 2.5 ml of media,
supplemented with antiretrovirals (ARVs) (100 nM elvitegravir
and 100–300 nM efavirenz) for the entire duration of culture
incubation. HDACi were added at specified concentrations on day
0 and cells or culture supernatants were harvested for the analysis
of HIV RNA at the indicated time points (6–48 hours or 6–7 days,
respectively). For HDACi pulse treatment, cultures were washed
twice using ARV-containing media at 4 or 24 hours after addition
of HDACi and incubated with ARVs until harvest. To measure
HIV RNA levels, 1 ml of culture supernatant was analyzed by a
robotic COBAS AmpliPrep/TaqMan system (Roche Diagnostics,
Indianapolis, IN), which extracts total nucleic acid and quantifies
HIV RNA in copies per milliliter using the HIV-1 Test, v2.0 kit
(Roche Diagnostics). For the measurement of cell-associated HIV
RNA levels, cells were washed with PBS, counted, and lysed
(Qiagen RLT buffer, 400 ml for every 2 million cells; Qiagen,
Venlo, Netherlands). Lysates were filtered through a Qiashredder
(Qiagen). Total RNA was prepared from the lysates (400 ml) using
a robotic system (QIAsymphony, Qiagen) that incorporates a
DNase I digestion step to eliminate cellular DNA. The resulting
total RNA was eluted with 200 ml of buffer, diluted to 1 ml with
nuclease-free water, and analyzed by COBAS using the HIV-1
Test v2.0 kit. Preparations of both cell-associated RNA and
supernatant total nucleic acids were tested for potential contam-
ination with HIV DNA and/or host DNA by performing the PCR
amplification in the presence and absence of reverse transcriptase
and by a detection of GAPDH-encoding host DNA sequence.
These methods confirmed that there was no contaminating HIV
DNA in either the intracellular RNA or supernatant total nucleic
acid preparations (Supplementary Figs. S3 and S4).
Cell activation analysis by flow cytometry
For cell activation analysis, either complete PBMC cultures or
resting CD4+ T cells isolated from HIV-infected cART-sup-
pressed patients were incubated with the tested agents under
specified conditions and were stained with relevant antibodies. All
antibodies were purchased from BD Biosciences and included
Alexa Fluor 700-labeled antibody to CD4, APC-H7-labeled
antibody to CD8, PE-Cy7 -labeled antibody to CD19, PE-labeled
antibody to CD69, APC-labeled antibody to CD25, and V450-
labeled antibody to HLA-DR. Live cells were gated by forward
and side scatter and exclusion of the dead cells by Live/Dead
Fixable Aqua Stain (Invitrogen). Marker staining was assessed by
flow cytometry analysis on a LSR Fortessa with data processing
using FlowJo software.
Cell-associated HDAC enzymatic assay
Resting CD4 T cells obtained from HIV-infected patients on
suppressive cART were incubated with serial dilutions of HDACi
in 96-well plates at 10,000 cells/well for indicated time and then
lysed by repeated freezing and thawing. Total cellular HDAC
activity was measured using the HDAC-Glo I/II assay kit
(Promega) according to the manufacturer’s protocol.
Phylogenetic analysis of HIV DNA and RNA during ex vivo
latency reversal
Single-genome sequencing of a portion of HIV-1 gag-pro-pol
amplified from cell culture supernatants or cellular DNA extracts
was performed as previously described [34–36]. Sequences were
aligned using ClustalW and neighbor-joining phylogenetic analysis
was performed using MEGA5. Trees were rooted on the subtype
B consensus sequence (www.hiv.lanl.gov).
Figure 8. Phylogenetic analysis of HIV sequences expressed ex
vivo following the latency reversal. Resting CD4 T cells isolated
from a cART-suppressed HIV-infected patient (high-responding patient
from Fig. 7) were treated continuously with RMD or activation control
(anti-CD3/CD28 antibodies). Single-genome sequencing was used to
analyze patient HIV proviral DNA and plasma RNA at the initiation of
treatment (day 0), together with the ex vivo induced HIV RNA in cell
culture supernatants at the end of treatment (day 7). Total of 43
sequences were recovered for proviral DNA. Eighty-eight, 11, and 4
sequences of HIV RNA were collected in culture supernatants following
the treatment with activation control, 7.5 nM RMD, and 2.5 nM RMD,
respectively. Grey arrows indicate examples of full concordance
between the sequence of proviral DNA and viral RNA induced either
by RMD or activation control. No HIV RNA sequences were recovered in
supernatants from cultures treated with control vehicle or 2 mM SAHA.
Identified HIV DNA and RNA sequences were aligned and the
phylogenetic tree was constructed using Clustal W and MEAG5.
doi:10.1371/journal.ppat.1004071.g008
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Experimental and statistical analyses
HIV RNA-induction experiments were conducted using 5 to 6
replicates for every experimental condition, including vehicle-
treated controls. Fold induction in HIV RNA levels was calculated
as a ratio of mean signals from compound-treated and vehicle
(DMSO)-treated control samples from the same donor under
identical conditions. Student’s t-test (one-tailed distribution, two-
sample equal variance) was used to assess statistical significance of
the difference between the detected HIV RNA copies in vehicle
control- and HDACi-treated samples or between RMD- and
VOR-treated samples. Time course experiments testing the
latency reversal agents had matching vehicle-treated controls for
each time point. For experiments using blood-derived resting CD4
T cells, culture supernatants from 3 replicate wells were combined
and analyzed using the COBAS system. Primary results in
absolute HIV RNA copy numbers from all experiments presented
in this study are provided in Supplementary material (Supple-
mentary Table S4).
Supporting Information
Figure S1 Effect of RMD and VOR on the viability of
primary memory CD4 cells.Memory CD4 cells were isolated
from HIV-infected patients and treated with RMD or VOR for 4
or 24 hours, respectively. Cell viability was determined using a
Cell TiterGlo reagent 6 days after the initiation of treatment and is
expressed as a percentage of cell viability relative to control
vehicle-treated memory CD4 cells from the same donors. The
data represent mean +/2 S.D. from three independent donors.
(TIF)
Figure S2 Effects of RMD and VOR on the expression of
activation markers in primary resting CD4+ T cells,
compared to the effect of PMA plus ionomycin stimula-
tion. Cells were treated with a 4-hour pulse of the indicated
concentrations of RMD or continuously with either VOR or
PMA+ ionomycin (positive control), followed by staining 48 hours
later. The surface expression of CD25 and CD69 in viable CD4
cells was analyzed by flow cytometry. Data are mean 6 SD of two
independent experiments performed with cells isolated from two
HIV-infected patients on suppressive cART.
(TIF)
Figure S3 Lack of HIV DNA contamination in extracted
intracellular RNA samples following the treatment with
DNase I. (A) Two million memory CD4 T cells isolated from
three HIV-infected cART-suppressed patients (Donors A–C) were
treated with control (blank, bk) or romidepsin (RMD) for
48 hours, washed, lysed, and filtered through a Qiagen shredder
to obtain homogenized cell lysates before additional analyses. Cell
lysates were extracted using QIAsymphony, with or without
DNase I digestion, before the entire sample was analyzed by
COBAS for the quantification of HIV viral sequences. (B) Cells
from identical donors were lysed, shredded, and then extracted for
total RNA using QIAsymphony with DNase I digestion. Samples
aliquots were analyzed by qPCR for HIV Gag and GAPDH
sequences, with or without addition of reverse transcriptase (RT+
or RT2). Asterisks (*) indicate none detected. (C) Random lysates
of vehicle-treated memory CD4 T cells from virally suppressed
HIV patients (#1–8) were divided into identical duplicates and
extracted for total RNA using QIAsymphony with DNase I
digestion. The total RNA was then treated with additional DNase
I digestion or not (yes vs. no) before quantification of HIV viral
sequences by COBAS.
(TIF)
Figure S4 Lack of HIV DNA contamination in total
nucleic acid extracts from cell culture supernatants.
Memory CD4 cells isolated from four HIV-infected cART-
suppressed patients (Donors A–D) were treated with no drug
control (blank; bk), 5 nM romidepsin (RMD) or PMA+ ionomycin
(P/I) for 6 days. Cell culture supernatants were extracted for total
nucleic acid (tNA) using COBAS TNAI kit before additional
analyses. (A) HIV Gag DNA and host GAPDH DNA were
quantified in tNA by qPCR without reverse transcriptase. Asterisks
(*) indicate none detected. (B) The same tNA samples were further
incubated with or without DNase I (yes vs. no), re-extracted for
tNA, and analyzed for HIV copies by COBAS HIV viral load
analyzer. Hash marks (#) indicate the limit of HIV quantification
(,20 copies/ml).
(TIF)
Table S1 Demographic characteristics of HIV-infected
patients participating in the study.
(XLS)
Table S2 HIV RNA released from resting CD4 T cells
treated with RMD can be pelleted by high-speed
centrifugation. a Percentage of total nucleic acid in the sample.
Resting CD4 T cells isolated from an HIV-infected patient on
suppressive cART were treated with RMD for 6 days and the
collected supernatants were subjected to ultracentrifugation
(21,000 g660 min). HIV DNA and RNA were quantified in
pellet and supernatant using Taqman quantitative PCR.
(DOCX)
Table S3 Systemic clinical exposures of RMD and VOR
compared to concentrations used in the ex vivo exper-
iments. a Istodax (romidepsin) prescribing information (www.
istodax.com). b Zolinza (vorinostat) prescribing information www.
zolinza.com/vorinostat/zolinza).c Determined by an equilibrium
dialysis followed by HPLC/mass spectrometry analysis. d Ratio of
free drug concentration in cell culture media and free drug
concentration in serum of clinically treated patients.
(DOCX)
Table S4 Summary of datasets from analyses of HIV
RNA induction in the ex vivo primary CD4 T cell cultures
isolated from virologically suppressed HIV-infected
patients. The table shows compiled primary data and statistical
analyses from the quantitation of HIV RNA (copies/million cells
for intracellular HIV RNA; copies/mL for supernatant HIV
RNA) in various types of CD4 T cell cultures isolated from HIV-
infected patients and treated with tested HDACi or vehicle
control. The datasets represent results displayed in Figures 2, 3, 4,
5, and 7.
(XLS)
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